dc.contributor.author | Hizal, Mutlu | |
dc.contributor.author | Bilgin, Burak | |
dc.contributor.author | Paksoy, Nail | |
dc.contributor.author | Acıkgöz, Özgür | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Gürbüz, Mustafa | |
dc.contributor.author | Sendur, Mehmet Ali Nahit | |
dc.contributor.author | İriağaç, Yakup | |
dc.date.accessioned | 2022-05-11T14:40:57Z | |
dc.date.available | 2022-05-11T14:40:57Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0171-5216 | |
dc.identifier.issn | 1432-1335 | |
dc.identifier.uri | https://doi.org/10.1007/s00432-021-03748-7 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/8987 | |
dc.description.abstract | Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.identifier.doi | 10.1007/s00432-021-03748-7 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Osimertinib | en_US |
dc.subject | Non-small cell lung cancer | en_US |
dc.subject | EGFR | en_US |
dc.subject | T790M | en_US |
dc.subject | Second line | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Therapy | en_US |
dc.subject | Program | en_US |
dc.subject | Time | en_US |
dc.title | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Cancer Research and Clinical Oncology | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-3353-344X | |
dc.authorid | 0000-0001-6235-7927 | |
dc.authorid | 0000-0001-7411-1705 | |
dc.authorid | 0000-0001-5147-4431 | |
dc.authorid | 0000-0001-7680-4142 | |
dc.institutionauthor | İriağaç, Yakup | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57195492869 | |
dc.authorscopusid | 57192957882 | |
dc.authorscopusid | 57205608177 | |
dc.authorscopusid | 56357909800 | |
dc.authorscopusid | 26039488700 | |
dc.authorscopusid | 57217738098 | |
dc.authorscopusid | 57205578251 | |
dc.authorwosid | Caner, Burcu/AAE-8549-2022 | |
dc.authorwosid | gülmez, ahmet/ABI-8218-2020 | |
dc.authorwosid | Yücel, Şebnem/AAY-6737-2021 | |
dc.identifier.wos | WOS:000679766900001 | en_US |
dc.identifier.scopus | 2-s2.0-85111543488 | en_US |
dc.identifier.pmid | 34331582 | en_US |